A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors

Diagnostic Pathology

Research

Naveena Singh¹  Pavel Fabian²  Petr Škapa³  Jana Drozenová⁴  W. Glenn McCluggage⁵  Gábor Méhes⁶  Sigurd F. Lax⁷  Jitka Hausnerová⁸  Oluwole Fadare⁹  Simona Stolnicu^1,10  David Cibula^1,11  Roman Kocian^1,11  Pavel Dundr^1,12  Romana Michálková^1,12  Kristýna Němejcová^1,12  Michaela Kendall Bártů^1,12  Ivana Stružinská^1,12  Radoslav Matěj^1,13  Jan Laco^1,14  Marián Švajdler^1,15 

[1] Department of Cellular Pathology, Barts Health NHS Trust, and Blizard Institute of Core Pathology, Queen Mary University of London, London, UK;Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic;Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic;Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic;Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK;Department of Pathology, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary;Department of Pathology, Hospital Graz II, Graz, Austria, and Johannes Kepler University Linz, Linz, Austria;Department of Pathology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic;Department of Pathology, University of California San Diego, San Diego, CA, USA;Department of Pathology, University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, Târgu Mureș, Romania;Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 12000, Prague, Czech Republic;Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic;Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic;Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic;Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic;The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Hradec Králové, Czech Republic;Šikl’s Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic;

关键词: IMP2;    IMP3;    Ovarian carcinoma;    Immunohistochemistry;   

DOI  :  10.1186/s13000-023-01300-4

 received in 2022-11-16, accepted in 2023-01-19,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundIMP2 and IMP3 are mRNA binding proteins involved in carcinogenesis. We examined a large cohort of ovarian tumors with the aim to assess the value of IMP2 and IMP3 for differential diagnosis, and to assess their prognostic significance.MethodsImmunohistochemical analyses with antibodies against IMP2 and IMP3 were performed on 554 primary ovarian tumors including 114 high grade serous carcinomas, 100 low grade serous carcinomas, 124 clear cell carcinomas, 54 endometrioid carcinomas, 34 mucinous carcinomas, 75 mucinous borderline tumors, and 41 serous borderline tumors (micropapillary variant). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher’s Exact test.ResultsWe found IMP2 expression (in more than 5% of tumor cells) in nearly all cases of all tumor types, so the prognostic meaning could not be analyzed. The positive IMP3 expression (in more than 5% of tumor cells) was most common in mucinous carcinomas (82%) and mucinous borderline tumors (81%), followed by high grade serous (67%) and clear cell carcinomas (67%). The expression was less frequent in endometrioid carcinomas (39%), low grade serous carcinomas (23%), and micropapillary variant of serous borderline tumors (20%). Prognostic significance of IMP3 could be evaluated only in low grade serous carcinomas in the case of relapse-free survival, where negative cases showed better RFS (p = 0.033).ConclusionConcerning differential diagnosis our results imply that despite the differences in expression in the different ovarian tumor types, the practical value for diagnostic purposes is limited. Contrary to other solid tumors, we did not find prognostic significance of IMP3 in ovarian cancer, with the exception of RFS in low grade serous carcinomas. However, the high expression of IMP2 and IMP3 could be of predictive value in ovarian carcinomas since IMP proteins are potential therapeutical targets.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

Fig. 2

42004_2023_830_Article_IEq3.gif